IgA antibody immunotherapy targeting GD2 is effective in preclinical neuroblastoma models.
Marjolein C StipMitchell EversMaaike NederendChilam ChanKarli R ReidingMirjam J DamenAlbert J R HeckSofia KoustoulidouRuud RamakersGerard C KrijgerRemmert de RoosEdouard SouteyrandAnnelisa M CornelMiranda P DierselhuisMarco JansenMark de BoerThomas ValeriusGeert van TeteringJeanette H W LeusenFriederike Meyer-WentrupPublished in: Journal for immunotherapy of cancer (2023)
IgA3.0 ch14.18 is a promising new therapy for neuroblastoma, showing (1) increased half-life compared to natural IgA antibodies, (2) increased protein stability enabling effortless production and purification, (3) potent CD89-mediated tumor killing in vitro by healthy subjects and patients with neuroblastoma and (4) antitumor efficacy in long-term mouse neuroblastoma models.